Biological
BG505 clinical trials
Keep track of what changes. Save the BG505 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 6
National Institute of Allergy and Infectious Diseases (NIAID) (3) · International AIDS Vaccine Initiative (3)
Often tested with
Tested in the same studies.
MEDI9197 (1) · Aluminum Hydroxide (1) · TRIMER 4571 (1)
Studies
Open first, then newest update. How each study uses BG505 is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedEnrolling by invitationPhase 1International AIDS Vaccine InitiativeNCT05983874Written as BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
- A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine CandidateNot yet recruitingPhase 1International AIDS Vaccine InitiativeNCT05863585Written as BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)
- Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05471076Written as BG505
- A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult ParticipantsActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05217641Written as BG505 MD39.3 mRNA
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04177355Written as BG505 SOSIP.664 gp140
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected AdultsCompletedPhase 1International AIDS Vaccine InitiativeNCT04224701Written as BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted